People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.
A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.